Login to Your Account



Regulatory NEWS
Hoping for a checkmate, generic drugmakers petitioned the Supreme Court Monday to either clear the board for a late May launch of generic versions of Copaxone or force Teva Pharmaceuticals USA Inc. to post a hefty bond to reimburse them for their losses if its final patent on the multiple sclerosis (MS) drug remains struck down on appeal.
The U.S. Patent and Trademark Office (PTO) is looking to the power of the crowd to strengthen the quality of patents by weeding out claims that aren't innovative.
Drugmakers' love for the FDA's orphan drug program burnt brightly in 2013. The agency granted three-quarters of the record 346 requests for orphan designations in fiscal 2013 and approved 33 orphan drugs for sale.
More Regulatory Headlines

Cast Your Vote

Has biotech’s bubble burst?: